We Have Developed An Automated Chemotherapy Dosing Optimization Tool. It Is A B2b Saas Platform That Is Inbuilt With 400+ Chemotherapy Protocols.
We Have Achieved End To End Automation For The Following Steps Involved In Chemotherapy Planning Process: Protocol Planning, Chemo Schedule, Consents, Adverse Event Based Dosing, Supportive Medication Plan, Instructions To Stakeholders, Hosp. Data Analytics.
Once The Treatment Provider Enters Treatment Regimen, Patient Profile And Lab Reports, The Tool Automatically Provides Treatment Options Based Upon Pre-fed Algorithms, Which Is Unique For Each Chemotherapy Regimen (~400 Regimens).
The Doses Are Individualized As Per Blood Reports, Adverse Events, Comorbidity And Individual Risk Of Emesis, Allergy, Febrile Neutropenia, Etc.
Startup Description
Startup Focuses On Developing Innovative Solutions In The Field Of Healthcare. We Aim To Build Solutions That Lead To Treatment Process Automation And Also Provide Data Analytics Solutions, Especially In Life Threatening Diseases With High Global Prevalence.
Our First Innovation Is In The Field Of Cancer Care. We Have Developed A Solution Named ‘aristo’ (Accurate Reliable Interface For Systemic Therapy In Oncology).
Product Screenshots
Business Model
Business Model Revolves Around 2 Revenue Streams – (I) Usage If Aristo As A Saas Platform (Ii) Analytics Of The Anonymized Data Generated Through Usage Of Aristo
(I) Aristo Will Be Offered On A Monthly Subscription Fee Basis To Chemotherapy Providers Across The Globe
Oncologists From 40-45 Countries Would Be Our Serviceable Addressable Mkt Out Of Total Mkt Of 187 Countries. Mkt Share Of ~1.5% Oncologists Would Lead To ~9 Mn Usd Turnover At End Of Y5 From Start Of Revenue
(Ii) Usage Of Aristo Would Lead To Declassified & Anonymized Data W.r.t. The Disease Profile, Prescription Trends, Sales Preferences And Outcomes – For Each Patient
Cancer Type Specific & Geography Specific Analytics Dashboards Based Upon These Data Points Would Be Provided To Stakeholders In Oncology – Pharma / Biotech, Clinical Research Organizations, Ai / Ml Companies
15% Of Above Customers Subscribing To Just 8 Out Of 40-45 Countries Covered By Aristo At Competitive Pricing Would Lead To ~17.6 Usd Mn Turnover At End Of Y5.
Customers
based in
Africa (excluding North Africa), Australia & New Zealand (Oceania), India, North America, Latin America, South Asia, East Asia, Middle East & North Africa, Southeast Asia, Europe
Business
Modal Type
SaaS
Type of
Sales
B2B
Competitors
Tempus (no like-to-like competition)
Ohum (no like-to-like competition)
Mednet (no like-to-like competition)
Teams
Girish Vijaykumar Korde
Founder, CEO
Dr. Ashay Karpe
Founder, CEO
Tell us a bit about how founding team knows
each other.
Close Friends Since 1994
Co-founders In Earlier Startup Of Chemotherapy Daycare Chain In India
Why did you decide to start this
company?
The Identified Problem And The Solution For The Problem Were Directly Related To Our Core Skills And Expertise
The Motivation To Positively Impact Millions Of Lives Led Us To Starting Midas Lifecare.
Are all the founders full-time on this
project?
No
Looking for an
opportunity to invest in companies
like Midas Lifecare International Pvt Ltd?
